Literature DB >> 11487583

Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.

J J Gorman1, J L McKimm-Breschkin, R S Norton, K J Barnham.   

Abstract

Segments of the cystine noose-containing nonglycosylated central subdomain, residues 149-197, of the attachment (G) glycoprotein of human respiratory syncytial virus (HRSV) have been assessed for impact on the cytopathic effect (CPE) of respiratory syncytial virus (RSV). Nalpha-acetyl residues 149-197-amide (G149-197), G149-189, and G149-177 of the A2 strain of HRSV protected 50% of human epithelial HEp-2 cells from the CPE of the A2 strain at concentrations (IC(50)) between 5 and 80 microm. Cystine noose-containing peptides G171-197 and G173-197 did not inhibit the CPE even at concentrations above 150 microm. Systematic C- and N-terminal truncations from G149-189 and G149-177 and alanine substitutions within G154-177 demonstrated that residues 166-170 (EVFNF), within a sequence that is conserved in HRSV strains, were critical for inhibition. Concordantly, G154-177 of bovine RSV and of an antibody escape mutant of HRSV with residues 166-170 of QTLPY and EVSNP, respectively, were not inhibitory. Surprisingly, a variant of G154-177 with an E166A substitution had an IC(50) of 750 nm. NMR analysis demonstrated that G149-177 adopted a well-defined conformation in solution, clustered around F168 and F170. G154-170, particularly EVFNF, may be important in binding of RSV to host cells. These findings constitute a promising platform for the development of antiviral agents for RSV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487583     DOI: 10.1074/jbc.M106288200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.

Authors:  Michael N Teng; Peter L Collins
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

3.  False cell lines: The problem and a solution.

Authors:  John R Masters
Journal:  Cytotechnology       Date:  2002-07       Impact factor: 2.058

4.  Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model.

Authors:  Hayat Caidi; Congrong Miao; Natalie J Thornburg; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  Antiviral Res       Date:  2018-04-17       Impact factor: 5.970

Review 5.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

6.  Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.

Authors:  Philip J Budge; Jacob Lebowitz; Barney S Graham
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

7.  The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans.

Authors:  Estela Escribano-Romero; Joanna Rawling; Blanca García-Barreno; José A Melero
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Identification of and human serum reactogenicity to neutralizing epitopes within the central unglycosylated region of the respiratory syncytial virus attachment protein.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Ann R Falsey; Edward E Walsh
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

9.  Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus.

Authors:  Eleanor R Gaunt; Rogier R Jansen; Yong Poovorawan; Kate E Templeton; Geoffrey L Toms; Peter Simmonds
Journal:  PLoS One       Date:  2011-03-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.